POLYCYSTIC KIDNEY DISEASE-TOLVAPTAN

SUMMARY

1. Blocks V2 receptors in distal nephron and collection duct. In PCKD: reduce cysts formation.

2. Prevents the binding of vasopressin, reduce expression of aquaporins.

3. Promotes water excretion: polyuria and potential dehydration.

4. Important to maintain adequate hydration to prevent activation of V1 receptors.

Reference(s)

Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].